Lymphohistiocytosis Clinical Trials

1 recruiting

Frequently Asked Questions

Common questions about Lymphohistiocytosis clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 19 of 9 trials

Recruiting
Phase 2Phase 3

Open-label Study of ELA026 in Participants With Secondary Hemophagocytic Lymphohistiocytosis (sHLH)

Secondary Hemophagocytic Lymphohistiocytosis (sHLH)
Electra Therapeutics Inc.156 enrolled37 locationsNCT05416307
Recruiting

Hemophagocytic Lymphohistiocytosis (HLH) Evaluation and Research of Clinical, ImmUnoLogic and TranscriptomE Study

Lymphohistiocytosis, HemophagocyticSecondary Hemophagocytic LymphohistiocytosisMacrophage Activation Syndrome+1 more
National Institute of Allergy and Infectious Diseases (NIAID)300 enrolled2 locationsNCT06339177
Recruiting
Not Applicable

Letermovir Prophylaxis in Children With EBV-Positive T/NK-Cell Lymphoproliferative Disease and Refractory/Relapsed EBV-Associated Hemophagocytic Lymphohistiocytosis

EBV-associated T/NK-cell Lymphoproliferative DiseasesRefractory/Relapsed EBV-related Hemophagocytic LymphohistiocytosisLetermovir
Beijing Children's Hospital80 enrolled1 locationNCT07488728
Recruiting
Phase 2Phase 3

Golidocitinib Combined With Selinexor for CAEBVD

EBVLymphohistiocytosisCAEBV
Beijing Friendship Hospital28 enrolled1 locationNCT07369739
Recruiting
Phase 2Phase 3

Prospective Single-Arm Clinical Trial of GO Regimen for HLH.

Lymphohistiocytosis, Hemophagocytic
Beijing Friendship Hospital28 enrolled1 locationNCT07339345
Recruiting
Phase 4

Zanubrutinib Combined With Rituximab in the Treatment of Secondary HLH in B-cell Lymphoma

Hemophagocytic Lymphohistiocytosis
The First Affiliated Hospital of Soochow University40 enrolled1 locationNCT07270835
Recruiting
Phase 3

A Phase III Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of Plonmarlimab in Subjects With Relapsed/Refractory Rheumatic and Immunologic Disease-associated Haemophagocytic Lymphohistiocytosis (Also Known as Macrophage Activation Syndrome [MAS])

Relapsed/Refractory Rheumatic and Immunologic Disease-associated Haemophagocytic Lymphohistiocytosis
TJ Biopharma Co., Ltd.30 enrolled15 locationsNCT07208058
Recruiting

Assessing the Presence of CT-DNA in Lymphoma Associated HLH

LymphomaHaemophagocytic Lymphohistiocytosis
Nottingham University Hospitals NHS Trust12 enrolled1 locationNCT05702502
Recruiting
Phase 1

Clinical Study of EBV-TCR-T Cells for EBV-associated Hemophagocytic Lymphohistiocytosis or EBV Infection

EBV InfectionEBV-associated Hemophagocytic Lymphohistiocytosis
Chinese PLA General Hospital9 enrolled1 locationNCT06135922